Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 190

1.

Programmed death-ligand 1 overexpression is a prognostic marker for aggressive papillary thyroid cancer and its variants.

Chowdhury S, Veyhl J, Jessa F, Polyakova O, Alenzi A, MacMillan C, Ralhan R, Walfish PG.

Oncotarget. 2016 Apr 12. doi: 10.18632/oncotarget.8698. [Epub ahead of print]

2.

ER maleate is a novel anticancer agent in oral cancer: Implications for cancer therapy.

Fu G, Somasundaram RT, Jessa F, Srivastava G, MacMillan C, Witterick I, Walfish PG, Ralhan R.

Oncotarget. 2016 Feb 26. doi: 10.18632/oncotarget.7751. [Epub ahead of print]

3.

Nuclear heterogeneous nuclear ribonucleoprotein D is associated with poor prognosis and interactome analysis reveals its novel binding partners in oral cancer.

Kumar M, Matta A, Masui O, Srivastava G, Kaur J, Thakar A, Shukla NK, RoyChoudhury A, Sharma M, Walfish PG, Michael Siu KW, Chauhan SS, Ralhan R.

J Transl Med. 2015 Aug 30;13:285. doi: 10.1186/s12967-015-0637-3.

4.

Anticancer Activity of Apaziquone in Oral Cancer Cells and Xenograft Model: Implications for Oral Cancer Therapy.

Srivastava G, Somasundaram RT, Walfish PG, Ralhan R.

PLoS One. 2015 Jul 24;10(7):e0133735. doi: 10.1371/journal.pone.0133735. eCollection 2015.

5.

Immunohistochemical Subcellular Localization of Protein Biomarkers Distinguishes Benign from Malignant Thyroid Nodules: Potential for Fine-Needle Aspiration Biopsy Clinical Application.

Ralhan R, Veyhl J, Chaker S, Assi J, Alyass A, Jeganathan A, Somasundaram RT, MacMillan C, Freeman J, Vescan AD, Witterick IJ, Walfish PG.

Thyroid. 2015 Nov;25(11):1224-34. doi: 10.1089/thy.2015.0114. Epub 2015 Aug 6.

PMID:
26131603
6.

Anticancer activity of pyrithione zinc in oral cancer cells identified in small molecule screens and xenograft model: Implications for oral cancer therapy.

Srivastava G, Matta A, Fu G, Somasundaram RT, Datti A, Walfish PG, Ralhan R.

Mol Oncol. 2015 Oct;9(8):1720-35. doi: 10.1016/j.molonc.2015.05.005. Epub 2015 May 21.

PMID:
26115765
7.

Prediction of recurrence-free survival using a protein expression-based risk classifier for head and neck cancer.

Chauhan SS, Kaur J, Kumar M, Matta A, Srivastava G, Alyass A, Assi J, Leong I, MacMillan C, Witterick I, Colgan TJ, Shukla NK, Thakar A, Sharma MC, Siu KW, Walfish PG, Ralhan R.

Oncogenesis. 2015 Apr 20;4:e147. doi: 10.1038/oncsis.2015.7.

8.

Post-operative stimulated thyroglobulin and neck ultrasound as personalized criteria for risk stratification and radioactive iodine selection in low- and intermediate-risk papillary thyroid cancer.

Orlov S, Salari F, Kashat L, Freeman JL, Vescan A, Witterick IJ, Walfish PG.

Endocrine. 2015 Sep;50(1):130-7. doi: 10.1007/s12020-015-0575-0. Epub 2015 Mar 20.

PMID:
25792004
9.

Induction of painless thyroiditis in patients receiving programmed death 1 receptor immunotherapy for metastatic malignancies.

Orlov S, Salari F, Kashat L, Walfish PG.

J Clin Endocrinol Metab. 2015 May;100(5):1738-41. doi: 10.1210/jc.2014-4560. Epub 2015 Mar 9.

PMID:
25751110
10.

Nuclear Ep-ICD expression is a predictor of poor prognosis in "low risk" prostate adenocarcinomas.

Assi J, Srivastava G, Matta A, MacMillan C, Ralhan R, Walfish PG.

PLoS One. 2015 Feb 19;10(2):e0107586. doi: 10.1371/journal.pone.0107586. eCollection 2015.

11.

Prognostic significance of cytoplasmic S100A2 overexpression in oral cancer patients.

Kumar M, Srivastava G, Kaur J, Assi J, Alyass A, Leong I, MacMillan C, Witterick I, Shukla NK, Thakar A, Duggal R, Roychoudhury A, Sharma MC, Walfish PG, Chauhan SS, Ralhan R.

J Transl Med. 2015 Jan 16;13:8. doi: 10.1186/s12967-014-0369-9.

12.

Nuclear Ep-ICD accumulation predicts aggressive clinical course in early stage breast cancer patients.

Srivastava G, Assi J, Kashat L, Matta A, Chang M, Walfish PG, Ralhan R.

BMC Cancer. 2014 Sep 29;14:726. doi: 10.1186/1471-2407-14-726.

13.

Mitogen activated protein kinase kinase kinase 3 (MAP3K3/MEKK3) overexpression is an early event in esophageal tumorigenesis and is a predictor of poor disease prognosis.

Hasan R, Sharma R, Saraya A, Chattopadhyay TK, DattaGupta S, Walfish PG, Chauhan SS, Ralhan R.

BMC Cancer. 2014 Jan 2;14:2. doi: 10.1186/1471-2407-14-2.

14.

Slug is a predictor of poor prognosis in esophageal squamous cell carcinoma patients.

Hasan MR, Sharma R, Saraya A, Chattopadhyay TK, DattaGupta S, Walfish PG, Chauhan SS, Ralhan R.

PLoS One. 2013 Dec 18;8(12):e82846. doi: 10.1371/journal.pone.0082846. eCollection 2013.

15.

The adenovirus 55 residue E1A protein is a transcriptional activator and binds the unliganded thyroid hormone receptor.

Arulsundaram VD, Webb P, Yousef AF, Pelka P, Fonseca GJ, Baxter JD, Walfish PG, Mymryk JS.

J Gen Virol. 2014 Jan;95(Pt 1):142-52. doi: 10.1099/vir.0.056838-0. Epub 2013 Oct 17.

16.

S100A7 overexpression is a predictive marker for high risk of malignant transformation in oral dysplasia.

Kaur J, Matta A, Kak I, Srivastava G, Assi J, Leong I, Witterick I, Colgan TJ, Macmillan C, Siu KW, Walfish PG, Ralhan R.

Int J Cancer. 2014 Mar 15;134(6):1379-88. doi: 10.1002/ijc.28473. Epub 2013 Oct 8.

17.

Transglutaminase 2 overexpression in tumor stroma identifies invasive ductal carcinomas of breast at high risk of recurrence.

Assi J, Srivastava G, Matta A, Chang MC, Walfish PG, Ralhan R.

PLoS One. 2013 Sep 13;8(9):e74437. doi: 10.1371/journal.pone.0074437. eCollection 2013.

18.

Clinical significance of altered expression of β-catenin and E-cadherin in oral dysplasia and cancer: potential link with ALCAM expression.

Kaur J, Sawhney M, DattaGupta S, Shukla NK, Srivastava A, Walfish PG, Ralhan R.

PLoS One. 2013 Jun 28;8(6):e67361. doi: 10.1371/journal.pone.0067361. Print 2013.

19.

Secretome proteins as candidate biomarkers for aggressive thyroid carcinomas.

Chaker S, Kashat L, Voisin S, Kaur J, Kak I, MacMillan C, Ozcelik H, Siu KW, Ralhan R, Walfish PG.

Proteomics. 2013 Mar;13(5):771-87. doi: 10.1002/pmic.201200356.

PMID:
23319340
20.

Iodine nutrition during pregnancy in Toronto, Canada.

Katz PM, Leung AM, Braverman LE, Pearce EN, Tomlinson G, He X, Vertes J, Okun N, Walfish PG, Feig DS.

Endocr Pract. 2013 Mar-Apr;19(2):206-11. doi: 10.4158/EP12193.OR.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk